Figure 1
![Duration of major hematologic response to dasatinib at 8 months' follow-up. Only 15 patients with a MaHR are included in this plot (2 of whom were censored with the same duration of response [195 days]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/7/10.1182_blood-2007-02-073528/2/zh80160706190001.jpeg?Expires=1720846305&Signature=CO9nERtVo5qTd9--Fmpj0LTbS70P16jJ0tQUsnyEiH3ww2-QumW~0tMxWvCQtYDNSEsQBbfAPq-L3JZXaDACjw97TGXSxLzp81KVqpnzZsv1SjykBJTwxVsP3ywnfOEIXLr62E6AqM72SaC00qllS1DmCBwvqrFOqh~W66TQhnBub8vGKMi23RNtp1lvWnO-3mOYwXYl6wWR4gBwV~Vu2C4wzlrZ8bSDSP-Jwoed-1whrnu38KlkDdcnXsB6OsOL4fxUicMaFhgx4C4K2Vu6zaPcIF0Cor1-~LDGzb6yZb9t-jSvpbvt4kLEu66i9xl~DFHpneeDmugAn2ErwwbjNw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Duration of major hematologic response to dasatinib at 8 months' follow-up. Only 15 patients with a MaHR are included in this plot (2 of whom were censored with the same duration of response [195 days]).
Duration of major hematologic response to dasatinib at 8 months' follow-up. Only 15 patients with a MaHR are included in this plot (2 of whom were censored with the same duration of response [195 days]).
